Tissue plasminogen activator in acute pulmonary embolism

Area of Science:

• Cardiology
• Pulmonary Medicine
• Pharmacology

Background:

• Thrombolytic therapy for acute myocardial infarction (AMI) has renewed interest in its use for acute pulmonary embolism (PE).
• Investigating recombinant human tissue-type plasminogen activator (rtPA) for acute PE treatment is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of rtPA in patients with acute PE.
• To compare rtPA with urokinase (UK) and heparin in managing PE.
• To assess the impact of rtPA on right ventricular function in PE patients.

Main Methods:

• An open-label study assessed rtPA's efficacy and safety.
• A comparative trial evaluated rtPA against an FDA-approved dose of urokinase (UK).
• Ongoing trials compare rtPA with a novel UK regimen and heparin, using echocardiography to assess right ventricular function.

Main Results:

• The open-label study demonstrated over 90% efficacy and safety for rtPA.
• rtPA showed more rapid and safer outcomes compared to UK in a prior trial.
• Ongoing trials are collecting data on rtPA's comparative effectiveness.

Conclusions:

• rtPA is a promising therapeutic agent for acute PE, demonstrating high efficacy and safety.
• Comparative studies are essential to establish optimal thrombolytic strategies for PE.
• Large-scale trials are needed to confirm the benefits of thrombolysis over heparin in reducing PE-related mortality and recurrence.